XBiotech Inc. (XBIT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, XBiotech reported revenue of $0. Net income was -$45.5M, or -$1.49 per diluted share. Operating activities generated -$39.9M of cash, leaving -$40.2M of free cash flow. At fiscal year end, XBiotech held $150.1M in total assets against $9.7M in total liabilities, including $125.6M of cash and equivalents.
Open the full interactive XBiotech financials → Quarterly statements, key ratios, valuation history and price charts.
XBiotech Key Stats
| Share Price | $2.16 |
|---|---|
| Market Cap | $65.9M |
| 52-Week Range | $2.12 – $2.94 |
| Shares Outstanding | 30.5 million (basic, 2026 Q2) |
XBiotech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $44.0M | $18.4M | $4.0M | $0 | $0 | $0 |
| Cost of Goods Sold | $34.5M | $5.8M | $651,000 | $0 | — | — |
| Gross Profit | $9.4M | $12.6M | $3.4M | $0 | — | — |
| Operating Income | -$18.3M | -$25.1M | -$34.5M | -$37.5M | -$42.5M | -$55.7M |
| Pre-Tax Income | -$12.8M | -$25.5M | -$33.6M | -$24.3M | -$38.6M | -$45.3M |
| Income Tax | -$1.6M | -$8.0M | -$688,000 | $244,000 | -$32,000 | $235,000 |
| Net Income | -$11.2M | -$17.4M | -$32.9M | -$24.6M | -$38.5M | -$45.5M |
| Diluted EPS | -$0.36 | -$0.58 | -$1.08 | -$0.81 | -$1.26 | -$1.49 |
XBiotech Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.0M | -$26.9M | -$5.5M | -$6.7M |
| Diluted EPS | — | -$0.88 | — | — |
XBiotech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $237.4M | $237.0M | $157.3M | $200.0M | $172.7M | $125.6M |
| Current Assets | $325.9M | $246.9M | $219.8M | $201.7M | $174.6M | $127.0M |
| Total Assets | $353.7M | $275.2M | $246.1M | $226.6M | $199.1M | $150.1M |
| Current Liabilities | $4.0M | $3.5M | $4.1M | $6.1M | $15.1M | $7.9M |
| Total Liabilities | $5.1M | $5.8M | $5.7M | $7.8M | $16.8M | $9.7M |
| Shareholders' Equity | $348.6M | $269.4M | $240.4M | $218.8M | $182.3M | $140.3M |
XBiotech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$65.1M | $69.4M | -$14.8M | -$18.7M | -$31.0M | -$39.9M |
| Cash From Investing | -$3.7M | -$3.5M | -$63.9M | $61.5M | -$1.3M | -$289,000 |
| Cash From Financing | -$409.7M | -$67.0M | $0 | -$9,000 | $10.4M | -$10.2M |
| Free Cash Flow | -$68.9M | $65.9M | -$15.4M | -$19.1M | -$32.3M | -$40.2M |
| Dividends Paid | — | $75.0M | $0 | — | — | — |
Figures from XBiotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full XBiotech financials page for every line item.
XBiotech Company Profile
| Ticker | XBIT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Austin, Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001626878 |
Frequently Asked Questions
What was XBiotech's revenue in fiscal 2025?
XBiotech (XBIT) reported revenue of $0 for fiscal 2025.
What is XBiotech's annual revenue history?
XBiotech's annual revenue by fiscal year: 2020: $44.0M; 2021: $18.4M; 2022: $4.0M; 2023: $0; 2024: $0; 2025: $0.
What was XBiotech's net income in fiscal 2025?
XBiotech reported net income of -$45.5M for fiscal 2025.
What was XBiotech's earnings per share (EPS) in fiscal 2025?
XBiotech's diluted EPS was -$1.49 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did XBiotech generate in fiscal 2025?
XBiotech generated -$40.2M of free cash flow in fiscal 2025.
What was XBiotech's revenue last quarter?
In its most recent reported quarter (2026 Q2), XBiotech reported revenue of $0.
How many shares of XBiotech are outstanding?
XBiotech reported a weighted average of 30.5 million basic shares outstanding in 2026 Q2.
What is XBiotech's market cap?
Based on its latest closing price, XBiotech (XBIT) has a market capitalization of about $65.9M.
When does XBiotech's fiscal year end?
XBiotech's fiscal year end, as registered with the SEC, is December 31.
Where is XBiotech headquartered?
XBiotech lists its business address in Austin, Texas in its SEC filings.